TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06549543

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Intensity Laser Therapy
Description: HILT is applied per session, with a maximum of 10.0 W, a mean of 5.7 W, a dose of 99 J/cm², and a total energy flux of 2079 J were applied over 6 minutes and 5 seconds on a 21 cm² field on the medial aspect of the knee joint.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: TENS is an analgesic modality of physical therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: TENS is an analgesic modality of physical therapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Hotpacks
Description: Hotpacks is a thermoanalgesia modality of physical therapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hotpacks
Description: Hotpacks is a thermoanalgesia modality of physical therapy

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: SHAM - High Intensity Laser Therapy
Description: for control group, sham HILT was applied, with lights on but no laser beam
Study: NCT06051708

Intervention type: OTHER
Intervention: standard AKI care bundle
Description: AKI care bundle include use of iv fluids, diuretics, antihyperkalemic drugs, sodium bicarbonate, antibiotics in septic patients.

Intervention type: OTHER
Intervention: standard care for hospitalized patients
Description: this includes iv fluids, diuretics, antibiotics in septic patients, other measures according to original disease
Study: NCT06416995

Intervention type: DIAGNOSTIC_TEST
Intervention: first trimester serum diagnostic test
Description: First trimester serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations predict adverse perinatal outcomes

Intervention type: DIAGNOSTIC_TEST
Intervention: first trimester serum diagnostic test
Description: First trimester serum vasohibin-1, vasohibin-2, cardiotropin-1 and endocan concentrations predict adverse perinatal outcomes
Study: NCT06514534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABL001/Asciminib
Description: The study treatment for this clinical trial is an investigational drug called asciminib, which is marketed under the brand name Scemblix®. Asciminib is a compound that is being evaluated for its efficacy and safety in the treatment of the target condition.~The minimum dose of asciminib to be administered in this study is 200 mg, while the maximum dose is 400 mg. The dose is planned as 200 mg twice a day (BID).~The drug will be administered orally, allowing for convenient and non-invasive administration.
Study: NCT06364293

Intervention type: OTHER
Intervention: Observational design does not include interventional behavior.
Description: Observational design does not include interventional behavior.
Study: NCT06210763

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Threshold IMT and traditional physical therapy program
Description: twenty ICU-acquired weakness elderly patients will receive chest physiotherapy (cough training, vibration, percussion, rib springing, and postural drainage), 30 minutes of resisted training on upper- and lower-limb muscles (15 min on upper limb and 15 min on lower limb), and 30 minutes of neuromuscular electrical stimulation of lower- and upper-limb muscles (triceps and wrist extensors, dorsiflexors, and quadriceps). sessions will be executed 5 times weekly). this Group will receive 3-set IMT (two sessions daily via threshold IMT, the set contain 10 repetitions) 5 times weekly. The study duration will be 1 month.
Study: NCT06131528

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Relaxation Breathing Exercises Group
Description: This group will preform Relaxation Breathing Exercises that includes Slow Deep Breathing, Pursed lip Breathing, Deep Diaphragmatic Breathing and Alternate Nostril Breathing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care Group
Description: The control group received lifestyle modifications that are an important part of hypertension management
Study: NCT06210763

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: traditional physiotherapy program
Description: twenty ICU-acquired weakness elderly patients will receive chest physiotherapy (cough training, vibration, percussion, rib springing, and postural drainage), 30 minutes of resisted training on upper- and lower-limb muscles (15 min on upper limb and 15 min on lower limb), and 30 minutes of neuromuscular electrical stimulation of lower- and upper-limb muscles (triceps and wrist extensors, dorsiflexors, and quadriceps). sessions will be executed 5 times weekly).
Study: NCT05792826

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BSZY Cream
Description: The patients receive BSZY Cream twice a day, in the morning and evening, for a period of four weeks.The patients can continue using their usual sunscreen and cleansing products, and their skin care steps should follow their daily habits. It is not recommended to add or replace any previously unused skin care products during the testing period.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: emulsion matrix
Description: The patients receive emusion matrix twice a day, in the morning and evening, for a period of four weeks.The patients can continue using their usual sunscreen and cleansing products, and their skin care steps should follow their daily habits. It is not recommended to add or replace any previously unused skin care products during the testing period.
Study: NCT05471258

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: monopolar dielectric diathermy
Description: The Experimental Group formed by 30 subjects will undergo an application of monopolar electrical diathermy by radiofrequency emission (MDR) using the Physicalm® device developed by the electro-medicine company Biotronic Advance Develops SL, on the lumbar muscles by means of rotary movements and translation, adapting to the muscle fibers of the lumbar area. A pulsed emission of 840 KHz and 30v will be made dynamically during a treatment time of 20 minutes. 3 weekly sessions will be performed for 3 weeks, a total of 9 treatment sessions.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control: Placebo
Description: The 30 participants in the control group will receive a placebo treatment, consisting of the same execution protocol as the EG, but with a non-emitting device whose software and hardware will be exactly the same as that used in the EG. The intervention will be simulated for 20 minutes.~3 weekly sessions will be held for 3 weeks, a total of 9 treatment sessions.
Study: NCT05299879

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiopulmonary exercise test, NT-proBNP, Echocardiography, 6 minute walk test, Right heart catheterization
Description: Screening for advanced HF with modified criteria from the Heart Failure Association of the European Society of Cardiology
Study: NCT06270420

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Technological Motor Rehabilitation
Description: Patients will undergo to motor treatment in the HoSmartAI room using one of the technological devices (i.e. OAK, VRRS Evo by Khymeia Group, Padova, Italy; AMADEO, PABLO by Tyromotion GmbH, Gratz, Austria), for the upper limb and lower limb motor recovery, balance and manual dexterity recovery. The duration of the treatment will be 15 sessions, 1 hour each, with daily frequency, 5 days a week, for a total of 3 weeks.
Study: NCT05232734

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine Citrate 20 MG/ML Oral Solution
Description: Caffeine syrup will be prepared by pharmacy laboratory and kept refrigerated (2-8C), to be used within 1 month from the date of preparation by pharmacy laboratory.
Study: NCT06430528

Intervention type: DRUG
Intervention: Osilodrostat
Description: Add methylprednisolone to osilodrostat therapy after first dose and continue during osilodrostat titration.
Study: NCT05613868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TPN-101
Description: 100 mg/ day up to 400mg/day of TPN-101
Study: NCT06656325

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Erchonia® FX405
Description: Procedure administrations with the Erchonia® FX-405 will be applied eight times during the 5-month procedure administration phase. Phase One involves one procedure administration each week for 4 consecutive weeks. Phase 2 commences for one month following the completion of Phase One and involves one procedure administration each month for the next four consecutive months. Each procedure administration with the Erchonia FX405 takes 10 minutes and will be administered by the test site.~Additionally, subjects will receive Scaling and Root Planing (SRP) prior to the administration of the first procedure with the Erchonia FX405, and a second time at the 3-month study midpoint assessment visit.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: Procedure administration with the Placebo Laser (emitting non therapeutic light) will be applied eight times during the 5-month procedure administration phase. Phase One involves one procedure administration each week for 4 consecutive weeks. Phase 2 commences for one month following the completion of Phase One and involves one procedure administration each month for the next four consecutive months. Each procedure administration with the Placebo Laser takes 10 minutes and will be administered by the test site.~Additionally, subjects will receive Scaling and Root Planing (SRP) prior to the administration of the first procedure with the Placebo Laser, and a second time at the 3-month study midpoint assessment visit.
Study: NCT06656611

Intervention type: OTHER
Group type: OTHER
Intervention: HPV self sampling
Description: Selected women will perform a vaginal self-sampling using a swab
Study: NCT06655961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Garden Activities Program
Description: When we look at the studies evaluating the effect of gardening activities on hospitalized children; it is seen that mostly children's opinions about therapeutic gardens are included and studies involving active gardening activities are limited. Shao et al. (2020) gave hospitalized children a task about garden plants and made them full this task through active participation and mobile games. However, it is seen that the gardening activity applied in this study was limited to a 5-minute task. The most important difference of our study from these studies is that a standardized gardening activity program will be applied to hospitalized children during their hospitalization and the active participation of the child will be ensured.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinical routine treatment and nursing care protocol
Description: Within the scope of the clinic routine treatment and nursing protocol; the decision to hospitalize the child, orientation to the clinic, execution of hospitalization paperwork, room placement, invasive intervention and treatment procedures are carried out. Treatment and care hours are revised according to individual order characteristics; 08.00-20.00, 08.00-16.00-00.00, 06.00-12.00-18.00-00.00 are planned considering the time order. 13.00-15.00 are the visiting hours. The child is not allowed to leave the clinic except for any medical purpose. No intervention will be applied to the control group of this study until the discharge process takes place.
Study: NCT06656533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated Transcranial magnetic stimulation (rTMS)
Description: Transcranial Magnetic Stimulation (TMS) involves a procedure where parts of the participants brain will be non-invasively (i.e. indirectly) stimulated by magnetic pulses. These magnetic pulses induce very brief activity in brain areas underlying the TMS coil. TMS will be performed by giving repetitive pulses (rTMS). rTMS has shown promise to reduce cortical hyperexcitability and to improve subjective measures of sleep quality and insomnia symptoms in patients with insomnia disorder. The goal of this study is to optimize the impact of rTMS therapy on sleep outcomes for patients with insomnia disorder.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Repeated Transcranial magnetic stimulation (rTMS)
Description: Transcranial Magnetic Stimulation (TMS) involves a procedure where parts of the participants brain will be non-invasively (i.e. indirectly) stimulated by magnetic pulses. These magnetic pulses induce very brief activity in brain areas underlying the TMS coil. TMS will be performed by giving repetitive pulses (rTMS). rTMS has shown promise to reduce cortical hyperexcitability and to improve subjective measures of sleep quality and insomnia symptoms in patients with insomnia disorder. The goal of this study is to optimize the impact of rTMS therapy on sleep outcomes for patients with insomnia disorder.
Study: NCT06586489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Natural Landscape Exposure
Description: Participants will view immersive virtual natural landscapes using virtual reality (VR) headsets for 10 minutes, three times a week, over eight weeks. They will choose the natural landscapes they wish to visit and admire, allowing for personalized engagement with the virtual environment.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Tablet Screen Natural Landscape Exposure
Description: Participants will watch immersive virtual natural landscapes on a tablet screen for 10 minutes, three times a week, over eight weeks. Participants can select the natural landscapes they prefer to view during the sessions, providing a personalized experience.
Study: NCT05888831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986449
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986449
Description: Specified dose on specified days
Study: NCT05912543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titration of FiO2
Description: The inhaled oxygen concentration after one-lung ventilation will be treated by the group.
Study: NCT04826757

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Coordinated care
Description: Coordinated care between general practioners; physiotherapists and occupational health services.~Early contact with occupational health service by the general practioner and use of occupational retention tool Active physiotherapy (Individual active, intensive and regular rehabilitation program with 15 sessions of 1 hour, at a rate of 2 or 3 sessions per week)
Study: NCT06488768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radial nerve block
Description: Ultrasound-guided Radial nerve block. Conducted with 10 mL of Lidocaine 2%. Ultrasound image are stored for documentation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Radial nerve block
Description: Ultrasound-guided Radial nerve block. Conducted with 10 mL of Lidocaine 2%. Ultrasound image are stored for documentation.
Study: NCT05597267

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIRIA Laser
Description: 4-6 experimental treatments at 4-6 weeks intervals
Study: NCT05292391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm-p80
Description: The Sm-p80 protein is formulated and lyophilized to yield the vaccine antigen, Sm-p80 for Injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm-p80 + GLA-SE
Description: Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm-p80 + GLA-SE
Description: Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm-p80 + GLA-SE
Description: Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm-p80 + GLA-SE
Description: Combination vaccine containing Sm-p80 antigen and GLA-SE adjuvant.
Study: NCT06697197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986482
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986482
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986482
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986482
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986482
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986482
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986482
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986482
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986482
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and rHuPH20
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab and rHuPH20
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab/relatlimab/rHuPH20
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab/relatlimab/rHuPH20
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Specified dose on specified days
Study: NCT06692335

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: High-Intensity Focused Ultrasound (HIFU)
Description: The HIFU treatment will utilize the Haifu JC 200 system under real-time ultrasound guidance, with participants positioned prone in a water-filled generator chamber. Conscious sedation will be administered using fentanyl and midazolam, adjusted based on pain tolerance. Acoustic output power will range from 300 to 400W.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: myomectomy
Description: Laparoscopic or open or hysteroscopic myomectomy will be performed.
Study: NCT06728085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baseline Assessment For Mother-Daughter Day HPV Campaign
Description: Pre-Implementation:~Identify, screen, and enroll mother-daughter dyads in the study to participate in the upcoming Mother-Daughter Day event on HPV vaccination and screening.~Complete baseline surveys with enrolled participants. Distribute reminder cards and send text messages to mother-daughter dyads who agree to participate in the mother-daughter day campaign.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Implement Mother-Daugther Day HPV Campaign
Description: Tailor and adapt to context: Mother-Daughter Day campaigns will be tailored and adapted to the local contexts within the 18 LGA.~Trained community health workers will implement the tailored Mother-Daughter Campaign by providing education on cervical cancer control and educational materials on HPV vaccination and HPV screening.~Engage mothers and daughters with on-site access to services: This includes offer of onsite vaccinations to girls by study nurse as well as offer of onsite self-collection screening kits to mothers and caregivers in a private area, along with instructions on how to use and return the sample.~Distribute gift bags with HPV vaccination cards, follow-up reminders, and linkage cards for participants with positive test results, as community health workers continue to provide onsite support and assistance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-Implementation Follow-Up
Description: A follow-up invitation will be sent to participate in a consultative phone call with study health workers to review self-collection results.~Participants with positive HPV test results will be linked to follow-up care and treatment.
Study: NCT05888831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986449
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days
Study: NCT05648474

Intervention type: DIAGNOSTIC_TEST
Intervention: Somatosensory evoked potential [SSEP] intraoperative monitoring
Description: No study specific intervention is performed. Intraoperative neuromonitoring system that is observed in this study is for assessing the health of the lumbar plexus during lateral lumbar interbody fusion surgery
Study: NCT06372717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-4098
Description: APL-4098 is administered orally in 28-day cycles
Study: NCT06375941

Intervention type: OTHER
Intervention: Observational
Description: Observational
Study: NCT06736821

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Open sinus augmentation with melatonin gel mixed with xenograft
Description: All Patients in this group underwent open sinus procedures to lift the sinus membrane followed by application of the melatonin gel which was mixed with xenograft as an augmentation material.~Preclinical studies proved the direct action of melatonin in enhancing the differentiation and proliferation of bone-forming osteoblasts. In addition to increasing bone mass, melatonin also facilitates new bone growth and osteointegration, making melatonin a particularly attractive molecule for use in bone implants when used alone or in combination with other growth factors

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open sinus augmentation with xenograft
Description: All Patients in this group underwent open sinus procedures to lift the sinus membrane followed by application of the xenograft as an augmentation material xenograft is used instead of autogenous bone graft to avoid the morbidity of the donor side
Study: NCT06739876

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable device-based intervention (with motivational support via social media)
Description: The wearable device-based intervention aims to reduce sedentary behavior as the Move alert function may facilitate the management of one's physical activity. Motivational support will be provided via an online community created using LINE platform. The platform serve for the following purposes: a) providing psychoeduation prior to the intervention; b) providing a place for participants to motivate and encourage each other; c) provide health knowledge to participants weekly, to motivate behavioral change; d) encouraging participants to upload their daily step count to the community page to motivate each other's progress; e) based on participant's performance, research assistants will provide tailored support using Line stickers designed for the present intervention; f) research assistants will monitor participants' step counts and provide prizes (vouchers) for those who had the most step counts and made the most improvements.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wearable device-based intervention (without support)
Description: The wearable device-based intervention aims to reduce sedentary behavior as the Move alert function may facilitate the management of one's physical activity.